Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2013

01-08-2013 | Preclinical Study

CX3CL1 expression is associated with poor outcome in breast cancer patients

Authors: Julia Y. S. Tsang, Yun-Bi Ni, Siu-Ki Chan, Mu-Min Shao, Ying-Kin Kwok, Kit-Wing Chan, Puay Hoon Tan, Gary M. Tse

Published in: Breast Cancer Research and Treatment | Issue 3/2013

Login to get access

Abstract

The significance of chemokines in cancer biology has been widely recognized in recent years. CX3CL1 is a unique subclass of chemokine with complex functions, including recruitment of anti-tumor leukocytes and promoting cancer survival, thus affecting cancer progression in both the directions. It is not clear how these different functions interact in breast cancers. This is further complicated by the heterogeneity of breast cancer, and differential association of CX3CL1 with different subgroups could be present. There is only limited knowledge of CX3CL1 expression profile, its relationship with different biological features, subtypes, and outcomes in breast cancers. In this study, CX3CL1 expression was examined in a large cohort of breast cancers by immunohistochemistry and its association with clinicopathological factors, biomarker expression, and impact on patients’ survival was assessed. High CX3CL1 expression was detected in 33.3 % (252/757) of primary invasive cancers. In line with its chemo-attractant function, CX3CL1 expression correlated positively with increased tumor infiltrating lymphocytes (TIL) (p = 0.005). In addition, CX3CL1 also correlated positively with adverse features in breast cancers, including lymph node involvement (p = 0.007), high Ki67 (p = 0.002), α-B crystallin expression (p = 0.008), and luminal B (worse prognosis luminal cancers) subtype (p = 0.024). Consistently, breast cancers with high expression of CX3CL1 were found to have a poorer overall survival (χ2 = 4.797, p = 0.029). Interestingly, the adverse effect of CX3CL1 on outcome appeared to be more prominent in cancers with low TIL. These findings indicated that CX3CL1 could also have a pro-tumor role in breast cancer, despite its previously suggested role in enhancing anti-tumor immunity. The results highlighted the complicated functions of CX3CL1 in breast carcinogenesis. Further studies are needed to clarify the relative contribution of these anti- and pro-tumor functions in order to understand the true prognostic and potential therapeutic values of CX3CL1.
Appendix
Available only for authorised users
Literature
3.
go back to reference Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385(6617):640–644. doi:10.1038/385640a0 PubMedCrossRef Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385(6617):640–644. doi:10.​1038/​385640a0 PubMedCrossRef
4.
go back to reference Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD (1998) Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188(8):1413–1419PubMedCrossRef Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD (1998) Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188(8):1413–1419PubMedCrossRef
5.
go back to reference Goda S, Imai T, Yoshie O, Yoneda O, Inoue H, Nagano Y, Okazaki T, Imai H, Bloom ET, Domae N, Umehara H (2000) CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol 164(8):4313–4320PubMed Goda S, Imai T, Yoshie O, Yoneda O, Inoue H, Nagano Y, Okazaki T, Imai H, Bloom ET, Domae N, Umehara H (2000) CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol 164(8):4313–4320PubMed
6.
go back to reference Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276(41):37993–38001. doi:10.1074/jbc.M106434200 PubMed Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276(41):37993–38001. doi:10.​1074/​jbc.​M106434200 PubMed
8.
go back to reference Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91(4):521–530PubMedCrossRef Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91(4):521–530PubMedCrossRef
9.
go back to reference Sciume G, Soriani A, Piccoli M, Frati L, Santoni A, Bernardini G (2010) CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. Neuro Oncol 12(7):701–710. doi:10.1093/neuonc/nop076 PubMedCrossRef Sciume G, Soriani A, Piccoli M, Frati L, Santoni A, Bernardini G (2010) CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. Neuro Oncol 12(7):701–710. doi:10.​1093/​neuonc/​nop076 PubMedCrossRef
10.
go back to reference Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M (2005) The high expression of fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 26(1):41–47PubMed Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M (2005) The high expression of fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 26(1):41–47PubMed
11.
go back to reference Hyakudomi M, Matsubara T, Hyakudomi R, Yamamoto T, Kinugasa S, Yamanoi A, Maruyama R, Tanaka T (2008) Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol 15(6):1775–1782. doi:10.1245/s10434-008-9876-3 PubMedCrossRef Hyakudomi M, Matsubara T, Hyakudomi R, Yamamoto T, Kinugasa S, Yamanoi A, Maruyama R, Tanaka T (2008) Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol 15(6):1775–1782. doi:10.​1245/​s10434-008-9876-3 PubMedCrossRef
12.
go back to reference Matsubara T, Ono T, Yamanoi A, Tachibana M, Nagasue N (2007) Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol 95(3):241–249. doi:10.1002/jso.20642 PubMedCrossRef Matsubara T, Ono T, Yamanoi A, Tachibana M, Nagasue N (2007) Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol 95(3):241–249. doi:10.​1002/​jso.​20642 PubMedCrossRef
13.
go back to reference Guo J, Chen T, Wang B, Zhang M, An H, Guo Z, Yu Y, Qin Z, Cao X (2003) Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 89(1):1–7PubMedCrossRef Guo J, Chen T, Wang B, Zhang M, An H, Guo Z, Yu Y, Qin Z, Cao X (2003) Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 89(1):1–7PubMedCrossRef
14.
go back to reference Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen M, Ren H (2007) Gene therapy with CX3CL1/fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther 14(16):1226–1234. doi:10.1038/sj.gt.3302959 PubMedCrossRef Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen M, Ren H (2007) Gene therapy with CX3CL1/fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther 14(16):1226–1234. doi:10.​1038/​sj.​gt.​3302959 PubMedCrossRef
15.
go back to reference Xin H, Kikuchi T, Andarini S, Ohkouchi S, Suzuki T, Nukiwa T, Huqun HK, Honjo T, Saijo Y (2005) Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 35(5):1371–1380. doi:10.1002/eji.200526042 PubMedCrossRef Xin H, Kikuchi T, Andarini S, Ohkouchi S, Suzuki T, Nukiwa T, Huqun HK, Honjo T, Saijo Y (2005) Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 35(5):1371–1380. doi:10.​1002/​eji.​200526042 PubMedCrossRef
16.
go back to reference Li F, Wang Z, Liu Y, Li J (2010) Down-regulation of fractalkine inhibits the in vitro and in vivo angiogenesis of the hepatocellular carcinoma HepG2 cells. Oncol Rep 24(3):669–675PubMed Li F, Wang Z, Liu Y, Li J (2010) Down-regulation of fractalkine inhibits the in vitro and in vivo angiogenesis of the hepatocellular carcinoma HepG2 cells. Oncol Rep 24(3):669–675PubMed
17.
go back to reference Erreni M, Solinas G, Brescia P, Osti D, Zunino F, Colombo P, Destro A, Roncalli M, Mantovani A, Draghi R, Levi D, Rodriguez YBR, Gaetani P, Pelicci G, Allavena P (2010) Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer 46(18):3383–3392. doi:10.1016/j.ejca.2010.07.022 PubMedCrossRef Erreni M, Solinas G, Brescia P, Osti D, Zunino F, Colombo P, Destro A, Roncalli M, Mantovani A, Draghi R, Levi D, Rodriguez YBR, Gaetani P, Pelicci G, Allavena P (2010) Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer 46(18):3383–3392. doi:10.​1016/​j.​ejca.​2010.​07.​022 PubMedCrossRef
19.
go back to reference Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A (2004) CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 64(14):4693–4698. doi:10.1158/0008-5472.CAN-03-3437 PubMedCrossRef Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A (2004) CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 64(14):4693–4698. doi:10.​1158/​0008-5472.​CAN-03-3437 PubMedCrossRef
20.
go back to reference Gaudin F, Nasreddine S, Donnadieu AC, Emilie D, Combadiere C, Prevot S, Machelon V, Balabanian K (2011) Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PLoS ONE 6(7):e21546. doi:10.1371/journal.pone.0021546 PubMedCrossRef Gaudin F, Nasreddine S, Donnadieu AC, Emilie D, Combadiere C, Prevot S, Machelon V, Balabanian K (2011) Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PLoS ONE 6(7):e21546. doi:10.​1371/​journal.​pone.​0021546 PubMedCrossRef
21.
go back to reference Marchesi F, Piemonti L, Fedele G, Destro A, Roncalli M, Albarello L, Doglioni C, Anselmo A, Doni A, Bianchi P, Laghi L, Malesci A, Cervo L, Malosio M, Reni M, Zerbi A, Di Carlo V, Mantovani A, Allavena P (2008) The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res 68(21):9060–9069. doi:10.1158/0008-5472.CAN-08-1810 PubMedCrossRef Marchesi F, Piemonti L, Fedele G, Destro A, Roncalli M, Albarello L, Doglioni C, Anselmo A, Doni A, Bianchi P, Laghi L, Malesci A, Cervo L, Malosio M, Reni M, Zerbi A, Di Carlo V, Mantovani A, Allavena P (2008) The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res 68(21):9060–9069. doi:10.​1158/​0008-5472.​CAN-08-1810 PubMedCrossRef
22.
23.
go back to reference Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC, Cristofanilli M (2006) Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 17(6):945–951. doi:10.1093/annonc/mdl053 PubMedCrossRef Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC, Cristofanilli M (2006) Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 17(6):945–951. doi:10.​1093/​annonc/​mdl053 PubMedCrossRef
24.
go back to reference Jamieson-Gladney WL, Zhang Y, Fong AM, Meucci O, Fatatis A (2011) The chemokine receptor CX(3)CR1 is directly involved in the arrest of breast cancer cells to the skeleton. Breast Cancer Res 13(5):R91. doi:10.1186/bcr3016 PubMedCrossRef Jamieson-Gladney WL, Zhang Y, Fong AM, Meucci O, Fatatis A (2011) The chemokine receptor CX(3)CR1 is directly involved in the arrest of breast cancer cells to the skeleton. Breast Cancer Res 13(5):R91. doi:10.​1186/​bcr3016 PubMedCrossRef
25.
go back to reference Park MH, Lee JS, Yoon JH (2012) High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J Surg Oncol 106(4):386–392. doi:10.1002/jso.23095 PubMedCrossRef Park MH, Lee JS, Yoon JH (2012) High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J Surg Oncol 106(4):386–392. doi:10.​1002/​jso.​23095 PubMedCrossRef
26.
go back to reference Lacroix M, Toillon RA, Leclercq G (2004) Stable ‘portrait’ of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 11(3):497–522PubMedCrossRef Lacroix M, Toillon RA, Leclercq G (2004) Stable ‘portrait’ of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 11(3):497–522PubMedCrossRef
27.
go back to reference Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, Orrico AR, Dreher D, Walters R, Parker J, Hu Z, He X, Palazzo JP, Olopade OI, Szabo A, Perou CM, Bernard PS (2006) Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8(2):R23. doi:10.1186/bcr1399 PubMedCrossRef Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, Orrico AR, Dreher D, Walters R, Parker J, Hu Z, He X, Palazzo JP, Olopade OI, Szabo A, Perou CM, Bernard PS (2006) Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8(2):R23. doi:10.​1186/​bcr1399 PubMedCrossRef
29.
go back to reference Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410PubMedCrossRef Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410PubMedCrossRef
30.
go back to reference Lakhani SR, Ellis IO, Schnitee SJ, Tan PH, van de Vijver MJ (eds) (2012) World Health Organisation classification of tumors of the breast, 4th edn. IARC Press, Lyon Lakhani SR, Ellis IO, Schnitee SJ, Tan PH, van de Vijver MJ (eds) (2012) World Health Organisation classification of tumors of the breast, 4th edn. IARC Press, Lyon
31.
go back to reference Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. doi:10.1200/JCO.2009.25.6529 PubMedCrossRef Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. doi:10.​1200/​JCO.​2009.​25.​6529 PubMedCrossRef
32.
go back to reference Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145. doi:10.1200/JCO.2006.09.2775 PubMedCrossRef Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145. doi:10.​1200/​JCO.​2006.​09.​2775 PubMedCrossRef
33.
go back to reference Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750. doi:10.1093/jnci/djp082 PubMedCrossRef Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750. doi:10.​1093/​jnci/​djp082 PubMedCrossRef
34.
go back to reference Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. doi:10.1093/annonc/mdr304 PubMedCrossRef Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. doi:10.​1093/​annonc/​mdr304 PubMedCrossRef
35.
go back to reference Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374. doi:10.1158/1078-0432.CCR-04-0220 PubMedCrossRef Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374. doi:10.​1158/​1078-0432.​CCR-04-0220 PubMedCrossRef
36.
go back to reference Huang YW, Su P, Liu GY, Crow MR, Chaukos D, Yan H, Robinson LA (2009) Constitutive endocytosis of the chemokine CX3CL1 prevents its degradation by cell surface metalloproteases. J Biol Chem 284(43):29644–29653. doi:10.1074/jbc.M109.045682 PubMedCrossRef Huang YW, Su P, Liu GY, Crow MR, Chaukos D, Yan H, Robinson LA (2009) Constitutive endocytosis of the chemokine CX3CL1 prevents its degradation by cell surface metalloproteases. J Biol Chem 284(43):29644–29653. doi:10.​1074/​jbc.​M109.​045682 PubMedCrossRef
38.
go back to reference Vitale S, Cambien B, Karimdjee BF, Barthel R, Staccini P, Luci C, Breittmayer V, Anjuere F, Schmid-Alliana A, Schmid-Antomarchi H (2007) Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut 56(3):365–372. doi:10.1136/gut.2005.088989 PubMedCrossRef Vitale S, Cambien B, Karimdjee BF, Barthel R, Staccini P, Luci C, Breittmayer V, Anjuere F, Schmid-Alliana A, Schmid-Antomarchi H (2007) Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut 56(3):365–372. doi:10.​1136/​gut.​2005.​088989 PubMedCrossRef
40.
go back to reference Moyano JV, Evans JR, Chen F, Lu M, Werner ME, Yehiely F, Diaz LK, Turbin D, Karaca G, Wiley E, Nielsen TO, Perou CM, Cryns VL (2006) AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116(1):261–270. doi:10.1172/JCI25888 PubMedCrossRef Moyano JV, Evans JR, Chen F, Lu M, Werner ME, Yehiely F, Diaz LK, Turbin D, Karaca G, Wiley E, Nielsen TO, Perou CM, Cryns VL (2006) AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116(1):261–270. doi:10.​1172/​JCI25888 PubMedCrossRef
41.
42.
go back to reference Adhikari AS, Singh BN, Rao KS, Rao ChM (2011) alphaB-crystallin, a small heat shock protein, modulates NF-kappaB activity in a phosphorylation-dependent manner and protects muscle myoblasts from TNF-alpha induced cytotoxicity. Biochim Biophys Acta 1813(8):1532–1542. doi:10.1016/j.bbamcr.2011.04.009 PubMedCrossRef Adhikari AS, Singh BN, Rao KS, Rao ChM (2011) alphaB-crystallin, a small heat shock protein, modulates NF-kappaB activity in a phosphorylation-dependent manner and protects muscle myoblasts from TNF-alpha induced cytotoxicity. Biochim Biophys Acta 1813(8):1532–1542. doi:10.​1016/​j.​bbamcr.​2011.​04.​009 PubMedCrossRef
43.
go back to reference Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567. doi:10.1016/j.stem.2007.08.014 PubMedCrossRef Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567. doi:10.​1016/​j.​stem.​2007.​08.​014 PubMedCrossRef
44.
go back to reference Tsang JY, Huang YH, Luo MH, Ni YB, Chan SK, Lui PC, Yu AM, Tan PH, Tse GM (2012) Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer. Breast Cancer Res Treat 136(2):407–417. doi:10.1007/s10549-012-2271-6 PubMedCrossRef Tsang JY, Huang YH, Luo MH, Ni YB, Chan SK, Lui PC, Yu AM, Tan PH, Tse GM (2012) Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer. Breast Cancer Res Treat 136(2):407–417. doi:10.​1007/​s10549-012-2271-6 PubMedCrossRef
45.
go back to reference Dubrovska A, Hartung A, Bouchez LC, Walker JR, Reddy VA, Cho CY, Schultz PG (2012) CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer 107(1):43–52. doi:10.1038/bjc.2012.105 PubMedCrossRef Dubrovska A, Hartung A, Bouchez LC, Walker JR, Reddy VA, Cho CY, Schultz PG (2012) CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer 107(1):43–52. doi:10.​1038/​bjc.​2012.​105 PubMedCrossRef
Metadata
Title
CX3CL1 expression is associated with poor outcome in breast cancer patients
Authors
Julia Y. S. Tsang
Yun-Bi Ni
Siu-Ki Chan
Mu-Min Shao
Ying-Kin Kwok
Kit-Wing Chan
Puay Hoon Tan
Gary M. Tse
Publication date
01-08-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2653-4

Other articles of this Issue 3/2013

Breast Cancer Research and Treatment 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine